DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Metabolic Dysfunction-Associated Steatohepatitis – Landscape & Forecast – Disease Landscape & Forecast (G7)
The market for metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), has great untapped potential owing to the disease’s high…
Metabolic Dysfunction-Associated Steatohepatitis | Disease Landscape & Forecast | G7 | 2025
The market for metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), has great untapped potential owing to the disease’s high…
GLP-1 receptor agonists – China In-Depth – GLP-1 Receptor Agonists – China In-Depth – China
China’s GLP-1 receptor agonist market is set for robust expansion, driven by the rising prevalence of type 2 diabetes (T2D), obesity, and comorbidities such as chronic kidney disease (CKD) and…
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Preserved Ejection Fraction (US)
Heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases. Even though physicians’ understanding of the disease’s pathophysiology…
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)
Drug treatment of heart failure with reduced ejection fraction (HFrEF) is well established, backed by a wealth of supporting evidence from clinical trials. RAAS inhibitors and beta blockers are the…
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Heart Failure (US)
Chronic heart failure (CHF) manifests as impaired cardiac function and consequent failure to maintain sufficient blood flow throughout the body to meet its metabolic demands. The CHF therapy market…
Metabolic Dysfunction-Associated Steatohepatitis | Disease Landscape & Forecast | G7 | 2024
The market for metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), has great untapped potential owing to the disease’s high…
